End of double-blind, placebo-controlled phase 1 trial with OPM-101: 104 healthy volunteers (VS) participated in this trial designed to assess...
Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN : FR001400CM63 ; Mnémonique : ALOPM), entreprise biopharmaceutique spécialisée en...
Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN : FR001400CM63 ; Mnémonique : ALOPM) (Paris:ALOPM), entreprise biopharmaceutique...
Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision...
DEMOCRITE Project: Demonstrating the efficiency of OPM-101 by targeting RIPK2 in Inflammatory Bowel Disease Regulatory News: Oncodesign Precision...
· R&D investment up 27% to €8.8 M, mainly linked to the clinical development of OPM-101 and the start of a preclinical program in oncology...
ANIMUS program: development of proprietary methods using AI to optimize molecules derived from our Nanocyclix® technology, for faster selection...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.